Biogen
Inc. (Nasdaq: BIIB) reported higher second quarter revenue and earnings of $3.93 per share compared with $3.01 per share a year earlier but
the biotechnology company cut its full year earnings outlook on slowing sales of its multiple
sclerosis drug Tecfidera. The stock price sank $85.02 to close at $300.03.
Biogen cuts outlook
July 24, 2015 at 18:43 PM EDT
